Biotech & Medtech
The best people, the best science.
Our experienced life science investors seek out visionary founders to translate novel scientific breakthroughs into clinically and commercially meaningful therapies.
We don’t just invest in ideas. We invest in people.
Lightstone Ventures was founded in 2012 to empower big-thinking founders with vision and commitment to bring innovative therapeutics to patients in need.
Our experience spans all stages of company growth
Our team collectively has nearly 100 years of company-building experience. We have been part of start-up ventures of all stages and played a critical role in evaluating, guiding, and building successful healthcare companies.
We are partners in company building
Fostering successful companies does not just mean writing a check. We not only back our companies financially, but we partner with them to navigate their day-to-day functions. Our team works hands-on with founders to help establish a strategy that can transform their vision into commercially viable products.
More than investors – we are guides
We invest with a long-term vision and patient capital that will fund the company through its life cycle from start-up to commercialization. Using a thesis-driven investment strategy, we focus on understanding key market sectors and seeking out disruptive technologies while building and nurturing relationships with key thought leaders.
Our reach is global
Our global footprint with offices in the U.S. and Ireland allows us to build a network with non-U.S. strategic and financial funding sources, as well as exploring novel development and commercialization strategies in these geographies.
Our portfolio companies succeed
Lightstone team members have been involved in some of the largest venture-backed life science exits over the last decade including: Ardian, Acceleron, ALX Oncology, Calithera BioSciences, Claret Medical, Disarm Therapeutics, MicroVention, Nimbus, Plexxikon, Portola Pharmaceuticals, Promedior, Proteolix, Ra Pharma, Tizona Therapeutics, Twelve and Zeltiq.
Big Ideas, Bright Futures.
We back driven entrepreneurs developing breakthrough therapies and technologies that have the potential to be industry-first or industry-leading products.
The success of a company is determined by its people, so we work closely with biotech and medtech founders to build teams with the experience and ambition necessary to achieve their goals.
Biotech
Our team looks for companies developing first-in-class drugs, across all modalities including small molecules, biologics and cell and gene therapies. We are focused on several disease areas including the central nervous system (CNS), immunology with particular interest in autoimmune diseases, next-generation approaches in oncology and ophthalmology.
Medtech
We look for founders with big ideas targeting the convergence of technology, medicine and consumer health. We see promise in companies focused on personalized medicines and targeted therapeutics that leverage data analytics and scientific platforms—groundbreaking medical technologies that address major diseases across immunology, cardiovascular, neurology and ophthalmology.
Acceleron Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The company successfully completed an IPO in 2013.
acceleronpharma.com- Lead:Jean George
- Fund:ATV
- Location:Cambridge, MA
Alchemab Therapeutics is using deep learning and cutting edge science to develop novel drugs for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies and the adaptive immune system.
alchemab.com- Lead:Jean George
- Fund:LSV
- Location:Cambridge, UK
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.
www.allaytx.com- Lead:Mike Carusi
- Fund:LSV Singapore
- Location:Menlo Park, CA and Singapore
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. The company successfully completed an IPO in 2020 (NASDAQ: ALXO).
alxoncology.com- Fund:LSV
- Location:South San Francisco, CA
Amber Therapeutics was founded in 2021 with a mission to develop an adaptive neuromodulation therapy that aims to be the first and only singular therapy able to treat mixed urinary incontinence (UUI and SUI).
amber-tx.com- Lead:Caroline Gaynor
- Fund:LSV
- Location:London, United Kingdom
Apreo Health is a development stage medical technology company that is developing innovative, globally applicable treatments for pulmonary disease.
thefoundry.com- Lead:Mike Carusi
- Fund:LSV, LSV Singapore
- Location:Menlo Park, CA
Ardian is a medical device company developing catheter-based therapies to treat hypertension and related conditions. Ardian was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2011.
- Lead:Hank Plain, Mike Carusi
- Fund:ATV, Morgenthaler
- Location:Mountain View, CA
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing novel therapeutics to prevent or reverse blindness.
atsenatx.com- Lead:Christina Isacson, Ph.D.
- Fund:LSV
- Location:Boston, MA
Avidia is a biopharmaceutical company discovering and developing a new class of human therapeutic proteins called Avimer™. The company was acquired by Amgen (NASDAQ: AMGN) in 2006.
amgen.com- Fund:Morgenthaler
- Location:Mountain View, CA
Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Ulthera in 2014.
- Lead:Hank Plain
- Fund:Morgenthaler
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. Its lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor and is now available through a unique digital business model of direct-to-patient solutions.
calahealth.com- Lead:Mike Carusi
- Fund:LSV
- Location:Burlingame, CA
Calithera Biosciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company successfully completed an IPO in 2014. Morgenthaler Ventures has exited the investment since IPO.
calithera.com- Lead:Jean George
- Fund:ATV, Morgenthaler
- Location:South San Francisco, CA
Developing the next generation of percutaneous left ventricular assist devices.
cardiacbooster.com- Lead:Mark Deem
- Fund:LSV
- Location:The Netherlands
Carrick Therapeutics is a biopharmaceutical company pioneering a portfolio of unique, first in class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.
carricktherapeutics.com- Lead:Caroline Gaynor
- Fund: LSV
- Location:Dublin, Ireland
Cerevance is a biopharmaceutical company that is taking a novel approach to the discovery and development of therapeutics for CNS and psychiatric diseases utilizing its powerful NETSseq target discovery platform.
cerevance.com- Lead:Jean George
- Fund:LSV
- Location:Boston, MA
Claret Medical is a medical device company developing innovative solutions for cerebral protection during structural heart and vascular interventions. The company was acquired by Boston Scientific (NYSE: BSX) in 2018.
claretmedical.com- Lead:Hank Plain
- Fund:LSV
- Location:Santa Rosa, CA
Contego Medical is a Raleigh-based medical device company developing a suite of products for the treatment of neurovascular, coronary and peripheral vascular disease.
contegomedical.com- Lead: Hanson S. Gifford, III
- Fund:LSV
- Location:Raleigh, North Carolina
Cyteir Therapeutics is a biopharmaceutical company and a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. The company successfully completed an IPO in 2021 (NASDAQ: CYT).
cyteir.com- Lead: Jean George
- Fund:LSV
- Location: Cambridge, MA
Disarm Therapeutics is a biotechnology company that is creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease-causing disability and disease progression. The company was acquired by Eli Lilly and Company (NYSE: LLY) in 2020.
disarmtx.com- Lead:Jean George
- Fund:LSV
- Location:Cambridge, MA
Elcelyx Therapeutics is a biopharmaceutical company developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones such as those that play an important role in glucose regulation.
elcelyx.com- Fund:Morgenthaler
- Location:San Diego, CA
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based and incisionless surgical technology for the treatment of GERD.
www.endogastricsolutions.com- Lead:Mike Carusi
- Fund:ATV
- Location:Redwood City, CA / Redmond, WA
FIRE1 is a medical device company developing novel remote monitoring devices to improve patient quality of life and outcomes while lowering overall healthcare costs.
fire1foundry.com- Lead:Caroline Gaynor
- Fund:LSV
- Location:Dublin, Ireland
FivePrime Therapeutics is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company successfully completed an IPO in 2013.
www.fiveprime.com- Lead:Jean George
- Fund:ATV
- Location:Boston, MA
Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company successfully completed an IPO in 2015.
flex-pharma.com- Lead:Jean George
- Fund:LSV
- Location:Boston, MA
ForSight VISION4 is a medical device company developing novel drug delivery therapies for the treatment of retinal diseases. The company was incubated within ForSight Labs and was acquired by Roche (OTCQX: RHHBY) in 2017.
- Fund:Morgenthaler
- Location:Menlo Park, CA
ForSight VISION5 is a medical device company focused on a novel anterior segment drug delivery program for ophthalmic drugs. The company was incubated within ForSight Labs and was acquired by Allergan (NYSE: AGN) in 2016.
- Fund:Morgenthaler
- Location:Menlo Park, CA
Gemini Therapeutics is a precision medicine company developing a broad, multimodal pipeline of first-in-class therapeutics for genetically-defined age-related macular degeneration and rare diseases.
geminitherapeutics.com- Lead: Jean George
- Fund:LSV, LSV Singapore
- Location:Cambridge, MA
Gynesonics is a medical device company focused on advancing women’s health by developing minimally invasive, transcervical, uterus-preserving and incision-free technologies for diagnostic and therapeutic applications.
gynesonics.com/us- Lead:Mike Carusi
- Fund:ATV
- Location:Redwood City, CA
Hydra, LLC (“Hydra”) is a biopharmaceutical developing drugs targeting novel ion channels for pain, inflammation, and respiratory disease.
hydrabiosciences.com- Lead:Jean George
- Fund:ATV
- Location:Cambridge, MA
Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders and circadian rhythm abnormalities. The company was acquired by Eli Lilly (NYSE: LLY) in 2007.
- Lead:Jean George
- Fund:ATV
- Location: Lexington, MA
MediSix Therapeutics is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia.
medisixtx.com- Lead:Mike Carusi, Christina Isacson, Ph.D.
- Fund: LSV Singapore
- Location:Boston, MA and Singapore
MicroVention is a medical device company developing and marketing innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels. The company was acquired by Terumo (TYO: 4543) in 2006.
www.microvention.com- Lead:Mike Carusi
- Fund:ATV
- Location:Tustin, CA
Moximed is a medical device company that is developing innovative devices for patients with osteoarthritis of the knee. The company was incubated within the ExploraMed incubator.
moximed.com- Fund:Morgenthaler
- Location:Hayward, CA
Nimbus Therapeutics is a biotechnology company focused on designing highly selective and potent medicines to disrupt known drivers of serious diseases. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences (NASDAQ: GILD) in 2016.
www.nimbustx.com- Lead:Jean George
- Fund:LSV
- Location:Cambridge, MA
Nuvaira is a medical device company developing novel devices for treating obstructive lung diseases. The company was incubated within The Foundry, the premier medical technology incubator.
www.nuvaira.com- Lead:Mike Carusi, Hank Plain
- Fund:ATV, Morgenthaler, LSV
- Location:Minneapolis, MN
Orexigen Therapeutics is a biopharmaceutical company developing therapies for the treatment of obesity. The company successfully completed an IPO in 2007.
www.nalpropion.com- Fund:Morgenthaler
- Location:La Jolla, CA
A NewCo focused on developing novel autoimmune therapies.
parvalistx.com- Lead:Caroline Gaynor
- Fund:LSV
- Location:Dublin, Ireland
Plexxikon is a biotechnology company developing novel small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo (TYO: 4568) in 2011
plexxikon.com- Lead:Mike Carusi
Portola Pharmaceuticals is a biopharmaceutical company developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company successfully completed an IPO in 2013.
portola.com- Lead:Jean George
- Location:South San Francisco, CA
PowerVision is a medical device company developing a proprietary fluid-controlled accommodating intraocular lens (IOL) technology to restore the vision of youth to millions of middle-aged or elderly individuals. The company was acquired by Alcon (NYSE: ALC) in 2019
powervisionlens.com- Lead:Mike Carusi
- Fund: ATV
- Location:Belmont, CA
Principia Biopharma is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency and longer duration of effect. Principia was acquired by Sanofi (NASDAQ: SNY) in 2020.
principiabio.com- Fund:Morgenthaler
- Location:Menlo Park, CA
Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. The company was acquired by Roche Holding (OTCMKTS: RHHBY) in 2019.
promedior.com- Fund:Morgenthaler
- Location:Lexington, MA
Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. The company was acquired by Onyx Pharmaceuticals (NASDAQ: ONXX) in 2009.
onyx.com- Lead:Jean George
- Fund:ATV
- Location:South San Francisco, CA
Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin. The company is developing a novel treatment solution for patients with symptomatic BPH designed to be safely and effectively performed in a doctor’s office setting in a simple procedure under local anaesthesia. LSV invested in 2022 to support the Company through its pivotal trial and pursuit of regulatory approval for the ProVee system in Europe and the US.
proverummedical.com- Lead:Caroline Gaynor
- Location:Dublin, Ireland
Psivant Therapeutics uses proprietary molecular simulation, computation and ML to rationally design small molecule drugs for dynamic protein targets of high value in inflammation and immunology.
psivant.com- Lead:Christina Isacson, Ph.D.
- Fund:LSV
- Location:Boston, MA
Ra Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules. The company successfully completed an IPO in 2016.
rapharma.com- Location:Cambridge, MA
Relievant Medsystems is a medical device company developing a new, minimally invasive technology that targets the source of chronic low back pain with a simple one-hour treatment.
relievant.com- Lead:Hank Plain
- Fund:Morgenthaler, LSV
- Location:Redwood City, CA
Reprieve Cardiovascular is a medical device company focused on automated fluid management technologies for acute heart failure treatment.
reprievecardio.com- Lead: Hanson S. Gifford, III
- Fund:LSV
- Location:Milford, MA
Scioderm is a clinical-stage biopharmaceutical company developing innovative therapies to address diseases with high unmet need, including rare diseases. The company was acquired by Amicus Therapeutics (NASDAQ: FOLD) in 2015.
- Fund:Morgenthaler
- Location:Durham, NC
Second Genome is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics identified using microbiome science.
secondgenome.com- Lead:Mike Carusi
- Fund:ATV, Morgenthaler
- Location:San Bruno, CA
SetPoint Medical is a clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases.
setpointmedical.com- Lead:Hank Plain
- Fund:Morgenthaler
- Location:Valencia, CA
Shoulder Innovations, Inc. is a medical device company developing and commercializing an innovative shoulder replacement system which addresses the greatest cause of surgical failure: glenoid loosening. This improved system is expected to improve patient outcomes and reduce overall system costs.
shoulderinnovations.com- Lead:Mike Carusi
- Fund:LSV
- Location:Holland, MI
Spine Wave is a medical device company developing and marketing novel devices for spine surgery, specifically spinal fusion, vertebral compression fracture repair and nucleus replacement and augmentation
spinewave.com- Fund:Morgenthaler
- Location:Shelton, CT
Tagworks Pharmaceuticals, pioneer of the Click-to-Release approach, is a precision therapy company, leveraging its technology platform, which is protected by a broad patent estate, to develop a new standard of care for patients suffering from severe diseases including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a clinically-validated, pan-carcinoma target that so far has remained out of reach of current ADC therapies. Tagworks’ technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index.
tagworkspharma.com- Lead:Christina Isacson, Ph.D.
- Fund:LSV
- Location:Netherlands and Boston, MA
Tallac Therapeutics is a biopharmaceutical company focused on the research and development of CpG-Antibody conjugates intended to stimulate the immune system in the treatment of cancer.
tallactherapeutics.com- Lead:Mike Carusi
- Fund:LSV
- Location:Burlingame, CA
Threshold Pharmaceuticals is a biotechnology company developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company successfully completed an IPO in 2005.
- Fund:Morgenthaler
- Location:South San Francisco, CA
Tizona Therapeutics is a clinical-stage immunotherapy company harnessing the power of the immune system to develop treatments for cancer. In 2020, Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of the company.
tizonatx.com- Lead:Jean George
- Fund:LSV
- Location:South San Francisco, CA
Transcend Medical is a medical device company focused on the development of devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. The company was acquired by Alcon (Novartis) (NYSE: NVS) in 2016.
- Fund:Morgenthaler
- Location:Menlo Park, CA
Trishula Therapeutics is a clinical stage company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody being studied in advanced cancers in multiple indications. In 2020, the company was spun off from Tizona Therapeutics when Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of Tizona.
trishulatx.com- Lead:Jean George
- Fund:LSV
- Location:South San Francisco, CA
Trotana Therapeutics is a San Diego based biotech company dedicated to the discovery and development of medicines targeting RNA binding proteins.
trotana.com- Lead: Jean George
- Location:San Diego, CA
Twelve is a medical device company developing a novel device for the treatment of chronic cardiovascular disease. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2015
- Lead:Hank Plain
- Location:Menlo Park, CA
Vapotherm is a medical device company pioneering Hi-VNI technology, a less invasive form of support for patients in respiratory distress. The company successfully completed an IPO in 2018.
vapotherm.com- Fund:Morgenthaler
- Location:Exeter, NH
Verastem is a biopharmaceutical company bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company successfully completed an IPO in 2012.
verastem.com- Lead:Jean George
- Fund:ATV
- Location:Cambridge, MA
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Vigil’s purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. Vigil is utilizing modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The company successfully completed an IPO in 2022 (NASDAQ: VIGL).
vigilneuro.com- Lead:Christina Isacson, Ph.D.
- Fund:LSV
- Location:Cambridge, MA
French Healthtech company developing AI software solutions to assist electrophysiologists during cardiac arrythmia procedures.
volta-medical.com- Lead:Caroline Gaynor
- Fund:LSV
- Location:France
Willow is a medical device company commercializing a wearable breast pump that allows women to achieve their breastfeeding goals without pressing pause on their own lives. The company, formerly known as NC7, was incubated within ExploraMed.
shop.willowpump.com- Lead:Mike Carusi
- Fund:LSV
- Location:Mountain View, CA
ZELTIQ is a medical device company developing and marketing a non-invasive, office-based procedure that uses Cryolipolysis, a proprietary cooling technology, to eliminate fat. The company successfully completed an IPO in 2011.
coolsculpting.com- Lead:Jean George
- Fund:ATV
- Location:Pleasanton, CA
A common passion for uncommon discoveries.
We are like-minded collaborators with a shared purpose: to integrate business and science into breakthrough companies that can change the lives of patients.
Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Allay Therapeutics, Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), Cala Health, EndoGastric Solutions, Gynesonics, MediSix Therapeutics, MicroVention (acquired by Terumo), Nuvaira, Plexxikon (acquired by Daiichi Sankyo), PowerVision (acquired by Alcon), Second Genome, Shoulder Innovations, Tallac Therapeutics, and Willow.
Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as an Adjunct Professor at the Tuck School of Business Administration at Dartmouth College. In addition, Mike has been heavily involved with several programs at Stanford University including the Stanford Biodesign Program and, more recently, the Stanford Center for Clinical and Translational Research and Education (Spectrum). Lastly, Mike served as a Director on the National Venture Capital Association (NVCA) Board of Directors and remains active in helping to shape policy affecting both innovation and healthcare.
Earlier in his career, Mike served as a Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm’s offices in London and San Francisco.
- Education: M.B.A. from the Tuck School of Business
B.S. in Mechanical Engineering from Lehigh University - Sector: Biopharmaceuticals, Medical Technology
- Location: Menlo Park
Representative Investments:
Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Cyteir Therapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).
Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec).
She has been in the biopharmaceutical industry for over 30 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division. Previously, Jean spent six years working in chemistry and bioresearch.
- Education: M.B.A. from Simmons College Graduate School of Management
B.S. from the University of Maine - Sector: Biopharmaceuticals
- Location: Boston
Representative Investments:
- Acceleron Pharma
- Alchemab Therapeutics
- Calithera Biosciences
- Cerevance
- Cyteir Therapeutics
- Disarm Therapeutics
- FivePrime Therapeutics
- Flex Pharma
- Gemini Therapeutics
- Hydra Biosciences
- Hypnion
- Nimbus Therapeutics
- Portola Pharmaceuticals
- Proteolix
- Tizona Therapeutics
- Trotana Therapeutics
- Verastem
- ZELTIQ
Hank Plain is a Special Partner of Lightstone Ventures. He also serves as a General Partner at Morgenthaler Ventures, which he joined in 2007 after more than 25 years in the pharma and medical device industry.
Mr. Plain began his career in 1980 with Eli Lilly. He left Lilly to become CEO of Perclose, where he led the company through a successful IPO and acquisition by Abbott Laboratories in 1999. Prior to becoming a venture capitalist, he co-founded eight medical device companies along with the team at The Foundry medical device incubator.
Mr. Plain serves on the boards of Nuvaira, Moximed and Setpoint. He previously served on the boards of nine companies that were acquired – Claret Medical, Miramar Labs, Twelve Medical, Ardian, Access Closure, Acclarent, Cabochon, EPI and TransVascular.
Mr. Plain is Chairman of the Board of Trustees for the Naval Postgraduate School Foundation in Monterey, CA and serves on the board of the First Tee of Monterey County.
- Education: B.S. in Finance from University of Missouri
- Sector: Medical Technology
- Location: Menlo Park
Representative Investments:
Hanson is a Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013.
Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV. Since its inception in 1998, Hanson has led The Foundry in all of its activities. These include the invention, identification and development of new technologies, the formation, financing, and staffing of over twenty new companies, and ongoing support of these new ventures as a board member. Success stories include Evalve (acquired by Abbott), Concentric (acquired by Stryker), Ardian (acquired by Medtronic), Twelve (acquired by Medtronic). At ForSight Labs, an Ophthalmology-focused incubator started by Hanson, Eugene de Juan, MD, and K. Angela Macfarlane, successes include Transcend Medical (acquired by Alcon), Forsight Newco 2 (acquired by QLT), Forsight Vision 4 (acquired by Genentech/Roche), and Forsight Vision 5 (acquired by Allergan).
Prior to The Foundry, Hanson was Vice President of Research and Development at Heartport, Inc., which had a successful IPO in 1996. From 1993-1998, he built and led a 62-person team at Heartport developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. In 1992-1993, Hanson co-founded and served as Managing Director of Bavaria Medizin Technologie, GmbH in Oberpfaffenhofen, Germany. In 1991, Hanson co-founded and served as President of Cardiovascular Therapeutic Technologies (acquired by Eli Lilly). From 1985-1990, Hanson worked at Devices for Vascular Intervention (acquired by Eli Lilly) in various engineering, clinical research and marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics.
Hanson is a named inventor on over 400 issued US patents. Hanson is a Director of FIRE1, Contego, Reprieve Cardiovascular, Half Moon Medical, Tangible Science, Apreo Health, and Mavericks Endo.
- Education: B.S. in Mechanical Engineering from Cornell University
- Sector: Medical Technology
- Location: Menlo Park
Representative Investments:
Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector. Christina has spent nearly 20 years in the biotech industry across operational roles and in venture capital. She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX).
Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy. Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock. Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development. In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I).
Originally trained as a Ph.D. in Neuroscience, leading the integration of science and medicine with business is a fundamental objective in her career.
- Education: Ph.D. Neuroscience from Tufts University School of Medicine, Graduate School of Biomedical Sciences
B.Sc. Biology from McGill University - Sector: Biopharmaceuticals
- Location: Boston
Representative Investments:
Caroline Gaynor is a Partner of Lightstone Ventures and focuses on new investments in the biopharmaceutical and medical device sectors out of the firm’s Dublin office. She currently serves as a board director for Parvalis Therapeutics, ProVerum, Carrick Therapeutics and FIRE-1 and as board observer for Volta Medical and Cerevance. She also previously served on the board of ALX Oncology. She is a council member of the Irish Venture Capital Association and a member of the BioInnovate Ireland Board of advisors.
Caroline joined Lightstone Ventures in 2017, bringing 15 years’ operational experience in the pharmaceutical industry and early stage medtech companies. Caroline spent 9 years at Bayer Healthcare, most recently serving on the board of senior management of Bayer Ltd. Ireland as head of market access, pricing and reimbursement. During her time in pharma she held a number of operational roles, predominantly focused on oncology, such as product management, strategic marketing, business development and regulatory/clinical affairs. Prior to Lightstone, and following completion of her BioInnovate fellowship in 2013, she co-led R&D on a device targeting Acute Pancreatitis and was subsequently involved in early pre-clinical, strategic clinical and commercial development at Vetex Medical.
In 2002 She received her degree in Pharmacy from Trinity College Dublin and subsequently went on to receive an M.Sc in Pharmaceutical Medicine in 2010.
- Education: B.S. in Pharmacy from Trinity College Dublin
M.S. in Pharmaceutical Medicine from Trinity College Dublin
M.S. in BioInnovation from National University of Ireland, Galway - Sector: Biopharmaceuticals, Medical Technology
- Location: Dublin
Representative Investments:
Mark is an Operating Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013.
Mark is a co-founder of the Foundry, LLC. The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over twenty new medical device companies. Success stories include Twelve (acquired by Medtronic), Ardian (acquired by Medtronic), eValve (acquired by Abbott), and Concentric (acquired by Stryker). Mark joined The Foundry at its inception in 1998. In addition to spearheading the research and invention process on new clinical opportunities, Mark led the early stage effort in The Foundry’s new companies until the company’s CEO and Senior Staff was hired.
Prior to joining The Foundry, Mark served in a founding role as consulting Director of Research and Development for Ventrica, Inc. Previously, Mark was a senior member of the Research & Development team at Medtronic Micro Interventional Systems. Mark joined MIS as one of the initial members of the company’s engineering team and remained there through the acquisition by Medtronic.
Previously, Mark held engineering positions with Devices for Vascular Engineering, Cordis Corporation and the USCI Division of C.R. Bard.
Mark has spent over thirty years in the design, testing and manufacture of medical devices. He is a co-inventor on over 250 issued and pending U.S. patents.
Mark serves as Chairman of the Board for Allay Therapeutics (formerly Foundry Therapeutics 1), is a Director for FIRE1, and Half Moon Medical and is a board observer for Nuvaira and Shoulder Innovations.
- Education: B.S. in Biomedical Engineering from Boston University
- Sector: Medical Technology
- Location: Menlo Park
Stacy is an Operating Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. She joined the LSV team in March 2016.
Since 2013, Stacy has also focused her work on engaging as a Professional Director, serving as an Independent Director and Committee Member for both public and venture-backed private companies across the healthcare ecosystem. Stacy currently serves as a non-executive Independent Director and member of the Compensation and Management Committee for Hill-Rom Holdings, Inc. (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc. (NASDAQ: LIVN). Stacy also serves as Chairwoman of the Board for both CALA Health and Contego, an Independent Director for Vesper Medical, as well as a Director for the Fogarty Institute, a non-profit educational innovator. Past Director appointments include PreCARDIA Inc, (exited to Abiomed), Claret Inc, (exited to Boston Scientific), Spirox, (exited to Entellus/Abbott) FIRE 1, (Covidien/Medtronic Investment), CVI (exited to Covidien/Medtronic) and Solace Therapeutics.
An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture.
Prior to Independent Director work, Stacy served as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career, Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee
engagement.
Stacy’s earlier work in medtech included sales and marketing leadership roles with SCIMED/Boston Scientific and sales and product management roles with American Hospital Supply/Baxter.
- Education: B.A. in Public Policy from Michigan State University
M.B.A. from Harvard University
Executive Course on Governance from Stanford Business School - Sector: Medical Technology
- Location: Menlo Park
Travis joined the Lightstone Ventures and Advanced Technology Ventures finance team in 2018. Travis is responsible for all aspects of accounting, tax, reporting, and compliance for LSV and ATV. Travis also serves as the Chief Financial Officer and Chief Compliance Officer at Morgenthaler Ventures, and Canvas Ventures. Travis began his career in PwC’s San Jose office where he spent five years in their Private Company Services group.
- Education: B.S. in Management Science from the University of California, San Diego
Certificate of Advanced Accounting Proficiency (CAAP) from Santa Clara University
Certified Public Accountant (inactive) - Location: Menlo Park
Brendan is a Vice President at Lightstone Ventures evaluating opportunities in the biopharmaceutical sector. Brendan has a background in medicinal chemistry and computational drug discovery research, and life sciences strategy.
Prior to Lightstone, Brendan was Director of New Product Planning at Q32 Bio, where he helped to define value propositions and commercial strategy for the company’s lead assets and discovery platform. Brendan was previously a life sciences strategy consultant at L.E.K. Consulting, working on projects across therapeutic areas, modalities and technologies, including pipeline optimization, go-to-market strategies, BD and M&A due diligence.
Brendan’s research at Stanford Computer Science, University of Toronto and Trinity College Dublin focused on computational methods of small molecule drug discovery for oncology and neuroscience targets. With his background in research and strategy, Brendan is keenly Interested in the intersection of innovative science, company formation and strategy, particularly in the pursuit of new therapeutics for patients in need.
- Education: Ph.D. Medicinal Chemistry, Trinity College Dublin Postdoc Computational Drug Discovery, Stanford University Postdoc Neuroscience Drug Discovery, University Health Network, University of Toronto
- Sector: Biopharmaceuticals
- Location: Boston
Olivia joined the Lightstone Ventures finance team in 2022. She was previously part of the Lightstone Ventures Singapore team, which she joined in 2017, with her most recent role being the Director of Operations. She began her career at PricewaterhouseCoopers Singapore where she focused on the financial services industry, specializing in the provision of regulatory advisory and audit services to banks and asset managers.
- Education: Bachelor of Accounting from Nanyang Technological University, Singapore
Certified Public Accountant (Australia) - Location: Menlo Park
Jingjing is a Vice President at Lightstone Ventures evaluating new biopharma investment opportunities. Jingjing has a background in neurobiology and life sciences strategy.
Before joining Lightstone, Jingjing was a Life Sciences Consultant at L.E.K. Consulting, where she worked on projects including target identification, opportunity assessment, corporate strategy, and commercial assessment for large pharmaceutical, mid-cap, and early-stage biotech companies. During her graduate studies, Jingjing was a senior fellow at the Office for Translation & Commercialization at Duke University assessing emerging technologies generated in laboratories at Duke.
- Education: Jingjing attained her Ph.D. in neurobiology at Duke University. Her research focused on the molecular and cellular mechanisms of retinal neural circuit formation and glial network development. With an integrated background in sciences and business, Jingjing is excited to help advance innovative life-changing therapeutics for patients in need.
- Sector: Biopharmaceuticals
- Location: Boston
Young is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio company management. He initially joined LSV in April 2021 as an Operating Partner.
Young is an accomplished executive with significant operating and venture capital experience.
He is currently the Chief Financial and Operating Officer at Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease.
Young is also a member of the board of directors of ADMA Biologics, (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.
Young held a variety of leadership roles over ten years as a senior executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. Young was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Young led public equity financings raising nearly $500 million, and led the company’s sale to J&J. Prior to Momenta, Young was a business development professional at Biogen, driving a variety of transactions. Young previously worked at Advanced Technology Ventures, working with the team on investments including Acceleron, Five Prime, Hypnion, and Zeltiq
- Education: Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University
B.S. in Biology from MIT - Sector: Biopharmaceuticals
- Location: Boston
Frank joined LSV in February 2023 and is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and support of our portfolio companies.
With over 25 years of global experience in product development and commercial leadership both in small biotech and large pharma, Frank served as Chief Executive Officer and member of the Board of Directors of Forma Therapeutics (FMTX) from March 2019 until its acquisition by Novo Nordisk for $1.1Billion in October 2022.
During his tenure at Forma, Frank transformed Forma from an early stage drug discovery company into one focused on the clinical development of lead assets in rare hematologic disorders and cancer. Frank led three equity financings raising approximately $700MM and built a patient centered organization.
Prior to Forma, Frank served as Senior Vice President, global product strategy and therapeutic area head for the immunology, ophthalmology and infectious diseases at Genentech, a member of the Roche Group. He was responsible for driving global development and commercialization strategy for the late stage portfolio and for global in-line product sales of $11 billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients and for driving the growth of multiple products to blockbuster / multi-blockbuster status in oncology, immunology, and ophthalmology.
Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly.
Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business.
He currently serves as Chairman of Catamaran Bio ( Private ) board of directors and as a member of the board of directors of Bolt Biotherapeutics Inc. (BOLT). Previously, he served on the board of directors of the Genentech Foundation.
- Education: B.S. in Chemical Engineering from Vanderbilt University
M.B.A. from the Wharton Graduate School of Business - Sector: Biopharmaceuticals
- Location: Boston
Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Proteolix was acquired by Onyx Pharmaceuticals in November 2009. Prior to joining Proteolix, Dr. Molineaux was Vice President of Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President of Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the immunology group at Merck, in Rahway, NJ.
- Education: B.S. in Biology from Smith College
Ph.D. in Molecular Biology from Johns Hopkins University
Postdoctoral fellowship at Columbia University - Sector: Biopharmaceuticals
- Location: Menlo Park
Previously Ken was a consultant to the life science industry. Most recently he was a senior partner and head of the European Life Sciences Practice at L.E.K. Consulting LLP. Prior to that he was a partner in the pharmaceutical practice at Booz-Allen & Hamiliton. Ken was also the founding partner and head of the European practice at The Wilkerson Group Ltd. Ken’s operating experience in discovery includes management roles at Cooper Life Sciences (to include Technicon), Becton Dickinson and Bethesda Research Labs.
Ken has served as a Board member of both public and private life science companies in Europe and the U.S. to include Intercept Pharmaceuticals Inc., Kailos Genetics and Orchid Biosciences.
During his academic career Ken authored more than 50 articles on the role of the cell surface in cell division.
- Education: B.S. in Biology from St. Joseph’s University
Ph.D. in Biochemistry from Princeton University - Sector: Biopharmaceuticals
- Location: Menlo Park
Representative Investments:
José-Alain Sahel, M.D., joined LSV in April 2024 as an Advisor. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and support of our portfolio companies. Dr. Sahel trained at Paris University Medical School, Louis Pasteur University, Strasbourg, and Harvard University. He is the Endowed Distinguished Professor and Chairman of the Department of Ophthalmology at the University of Pittsburgh School of Medicine/UPMC. He founded and directed the Vision Institute (Sorbonne Université-Inserm-CNRS) in 2008 in Paris, France, and the Vision Institute at UPMC, which opened in May 2023, two of the world’s largest interdisciplinary research centers. His work has contributed to understanding and preventing vision loss from photoreceptor cell degeneration and developing several novel vision restoration strategies. He conducted dozens of clinical trials on retinal conditions, including the first in human trials of artificial retina, gene therapy, and optogenetics. He co-authored over 700 peer-reviewed articles and 90 patents. He has co-founded companies developing innovative therapies for vision restoration. He is a member of the Académie des Sciences-Institut de France, the Académie des Technologies, the Association of American Physicians, the American Ophthalmology Society, the German National Academy of Sciences Leopoldina, and a fellow of the National Academy of Inventors. He holds an Honoris Causa Doctorate from the University of Geneva and the Chaire d’Innovation Technologique Liliane Bettencourt at Collège de France (2015-2016). He is an Officer of the Ordre National de la Légion d’Honneur and Commander of the National Order of Merit (France). He received, among numerous awards, the Alcon Research Institute Award for Excellence in Vision Research, the Grand Prix NRJ-Neurosciences-Institut de France, the 2015 Foundation Fighting Blindness Llura Liggett Gund Lifetime Achievement Award, the Médaille Grand Vermeil, Ville de Paris (2019), the 2021 Breakthrough in the Life Sciences – Falling Walls Foundation, Berlin, Germany, the 2022 Chica and Heinz Schaller Foundation Award for Translational Neuroscience, the 2023 International Prize for Translational Neuroscience from the Max Planck Society, Germany and the 2024 Michaelson Award from the Macula Society. President Macron appointed him to the Conseil Présidentiel de la Science in Dec. 2023.
- Education: Paris University Medical School, Louis Pasteur University, Strasbourg, and Harvard University
- Sector: Biopharmaceuticals
- Location: Boston
Doug Treco, PhD, was a co-founder of Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until its acquisition by UCB in April 2020. Previously, he was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc in 2005. Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.
Hong I. Wan, Ph.D. is president, chief executive officer and co-founder of Tallac Therapeutics. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation
- Education: Ph.D. in Molecular and Cell Biology from University of California, Berkeley
A.B. in Biochemical Sciences from Harvard University - Sector: Biopharmaceuticals
- Location: Menlo Park